For EVO301 in moderate-to-severe atopic dermatitis and plans to advance the IL-18 inhibitor into a Phase 2b dose-ranging trial
https://finviz.com/quote.ashx?t=EVMN&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.